Rebecca Varney
Family · Saint Paul, VANPI 1609865211
Payments from drug & device makers
Across 44 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$143
- AstraZeneca$110
- Abbott$103
- Novo Nordisk$91
- Integra Lifesciences Corporation$64
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
- plus $347 from 11 others
What the payments were for
- Food & beverage$919100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $143 |
| AstraZeneca | 7 | $110 |
| Abbott | 2 | $103 |
| Novo Nordisk | 6 | $91 |
| Integra Lifesciences Corporation | 2 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $60 |
| AbbVie | 3 | $53 |
| Lilly USA, LLC | 2 | $46 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Bayer | 2 | $40 |
| Boehringer Ingelheim | 2 | $34 |
| GSK | 2 | $31 |
| Pfizer | 2 | $30 |
| Optinose US, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$919 in reported general payments places this provider in the 65th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $147,366 |
| OzempicSemaglutide | 104 | $109,705 |
| MounjaroTirzepatide | 83 | $100,711 |
| JardianceEmpagliflozin | 69 | $66,331 |
| FarxigaDapagliflozin Propanediol | 53 | $62,765 |
| JanuviaSitagliptin Phosphate | 65 | $51,455 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $48,490 |
| TrulicityDulaglutide | 41 | $43,585 |
| VraylarCariprazine Hcl | 21 | $33,207 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $31,147 |
| Bydureon BciseExenatide Microspheres | 25 | $24,898 |
| XareltoRivaroxaban | 24 | $24,499 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $22,712 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $20,819 |
| MyrbetriqMirabegron | 28 | $18,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $30 | $157,796193 claims |
| Lilly USA, LLCMounjaro, Trulicity | $46 | $144,297124 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium, Brilinta | $110 | $114,129171 claims |
| Novo NordiskOzempic | $91 | $109,705104 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $34 | $71,52880 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $31 | $65,43392 claims |
| AbbVieVraylar, Linzess, Synthroid | $53 | $54,093133 claims |
| Astellas Pharma US IncMyrbetriq | $143 | $18,62828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,332 family providers in Virginia.
Other family in Saint Paul
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.